News
Novartis CAR-T safety in FDA spotlight
FDA advisers are set to make recommendations on Novartis’ groundbreaking CAR-T therapy CTL019 tomorrow – and are set to focus on safety concerns in the decisive meeting.
Sunday 5 April 2026
